You can buy or sell Imara and other stocks, options, ETFs, and crypto commission-free!
Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. Read More The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA. The listed name for IMRA is IMARA Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 13, Pre-Market